NCT06946238View on ClinicalTrials.gov

Single-fraction APBI for Early-stage Breast Cancer With Favorable Histological Subtypes (Breast-1F)

NARecruitingINTERVENTIONAL
Enrollment

311

Participants

Timeline

Start Date

July 25, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2035

Conditions
Breast Cancer
Interventions
RADIATION

Adjuvant single-fraction accelerated partial breast irradiation

Experimental arm (arm 1-single-fraction APBI) patients will be treated to a total dose (TD) of 15.5 Gy to the PTV with a simultaneous integrated boost (SIB) to a TD of 21 Gy to the tumor bed, while arm 2-five-fractions APBI patients with 30 Gy/ 5 fractions to PTV.

Trial Locations (1)

20132

RECRUITING

IRCCS San Raffaele Scientific Institute, Milan

All Listed Sponsors
lead

IRCCS San Raffaele

OTHER

NCT06946238 - Single-fraction APBI for Early-stage Breast Cancer With Favorable Histological Subtypes (Breast-1F) | Biotech Hunter | Biotech Hunter